Denmark · Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 24.66 billion. The enterprise value is 8.48 billion.
| Market Cap | 24.66B |
| Enterprise Value | 8.48B |
Important Dates
The last earnings date was Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.38 million shares outstanding. The number of shares has increased by 18.37% in one year.
| Current Share Class | 70.99M |
| Shares Outstanding | 70.38M |
| Shares Change (YoY) | +18.37% |
| Shares Change (QoQ) | +1.58% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 51.05% |
| Float | 60.49M |
Valuation Ratios
The trailing PE ratio is 3.74 and the forward PE ratio is 4.06.
| PE Ratio | 3.74 |
| Forward PE | 4.06 |
| PS Ratio | 2.71 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | 3.28 |
| P/OCF Ratio | 3.27 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.18, with an EV/FCF ratio of 1.13.
| EV / Earnings | 1.27 |
| EV / Sales | 0.93 |
| EV / EBITDA | 1.18 |
| EV / EBIT | 1.18 |
| EV / FCF | 1.13 |
Financial Position
The company has a current ratio of 15.09, with a Debt / Equity ratio of 0.03.
| Current Ratio | 15.09 |
| Quick Ratio | 15.08 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.05 |
| Interest Coverage | 25.64 |
Financial Efficiency
Return on equity (ROE) is 53.44% and return on invested capital (ROIC) is 34.83%.
| Return on Equity (ROE) | 53.44% |
| Return on Assets (ROA) | 32.86% |
| Return on Invested Capital (ROIC) | 34.83% |
| Return on Capital Employed (ROCE) | 44.76% |
| Revenue Per Employee | 23.66M |
| Profits Per Employee | 17.35M |
| Employee Count | 335 |
| Asset Turnover | 0.67 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zealand Pharma has paid 534.00 million in taxes.
| Income Tax | 534.00M |
| Effective Tax Rate | 7.40% |
Stock Price Statistics
The stock price has decreased by -61.52% in the last 52 weeks. The beta is 0.55, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -61.52% |
| 50-Day Moving Average | 372.73 |
| 200-Day Moving Average | 572.08 |
| Relative Strength Index (RSI) | 49.79 |
| Average Volume (20 Days) | 369,217 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 9.11 billion and earned 6.68 billion in profits. Earnings per share was 93.68.
| Revenue | 9.11B |
| Gross Profit | 9.12B |
| Operating Income | 7.19B |
| Pretax Income | 7.21B |
| Net Income | 6.68B |
| EBITDA | 7.19B |
| EBIT | 7.19B |
| Earnings Per Share (EPS) | 93.68 |
Balance Sheet
The company has 16.58 billion in cash and 396.95 million in debt, giving a net cash position of 16.18 billion or 229.90 per share.
| Cash & Cash Equivalents | 16.58B |
| Total Debt | 396.95M |
| Net Cash | 16.18B |
| Net Cash Per Share | 229.90 |
| Equity (Book Value) | 15.61B |
| Book Value Per Share | 220.68 |
| Working Capital | 15.89B |
Cash Flow
In the last 12 months, operating cash flow was 7.54 billion and capital expenditures -14.31 million, giving a free cash flow of 7.53 billion.
| Operating Cash Flow | 7.54B |
| Capital Expenditures | -14.31M |
| Free Cash Flow | 7.53B |
| FCF Per Share | 106.97 |
Margins
Gross margin is 100.06%, with operating and profit margins of 78.88% and 73.34%.
| Gross Margin | 100.06% |
| Operating Margin | 78.88% |
| Pretax Margin | 79.20% |
| Profit Margin | 73.34% |
| EBITDA Margin | 78.98% |
| EBIT Margin | 78.88% |
| FCF Margin | 82.64% |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.37% |
| Shareholder Yield | n/a |
| Earnings Yield | 27.09% |
| FCF Yield | 30.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |